한국피셔과학

비상장계속사업자

Fisher Scientific Korea Ltd.

토니아끼아리토

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

한국피셔과학

Business Reg. No. 1068150277 · CEO 토니아끼아리토

I.Investment Overview

Target한국피셔과학 (1068150277)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명한국피셔과학
영문명Fisher Scientific Korea Ltd.
대표자토니아끼아리토
사업자등록번호1068150277
법인등록번호1101111075286
설립일1994.09.12

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW365.72021471.52022499.720234492024440.32025
영업이익100M KRW27.6202128.2202213.720233.8202420.72025
순이익100M KRW22.3202121202211.820237.2202418.62025
Item20252024202320222021
자산총계342.9억원331억원321.6억원341.2억원321.2억원
부채총계88.2억원94.9억원92.6억원84.1억원85.2억원
자본총계254.7억원236.1억원228.9억원257.1억원236.1억원
매출액440.3억원449억원499.7억원471.5억원365.7억원
영업이익20.7억원3.8억원13.7억원28.2억원27.6억원
순이익18.6억원7.2억원11.8억원21억원22.3억원

VI.Financial Ratios

FY2025 basis

4.7%

영업이익률

4.23%

순이익률

5.43%

ROA

7.3%

ROE

34.6%

부채비율

74.29%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

한국피셔과학 투심보고서 | Alpha Lenz